RENAU.UNSP.ARD 1/5 EO-20 (56S0) - Total Liabilities
Based on the latest financial reports, RENAU.UNSP.ARD 1/5 EO-20 (56S0) has total liabilities worth €3.67 Billion EUR (≈ $4.29 Billion USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 56S0 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
RENAU.UNSP.ARD 1/5 EO-20 - Total Liabilities Trend (2022–2025)
This chart illustrates how RENAU.UNSP.ARD 1/5 EO-20's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is RENAU.UNSP.ARD 1/5 EO-20's balance sheet.
RENAU.UNSP.ARD 1/5 EO-20 Competitors by Total Liabilities
The table below lists competitors of RENAU.UNSP.ARD 1/5 EO-20 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Vale S.A
BA:VALE
|
Argentina | AR$48.91 Billion |
|
Heico Corporation
NYSE:HEI
|
USA | $4.20 Billion |
|
Norsk Hydro ASA
OL:NHY
|
Norway | Nkr97.89 Billion |
|
Vonovia SE
XETRA:VNA
|
Germany | €60.17 Billion |
|
China Shipbuilding Industry Co Ltd
SHG:601989
|
China | CN¥135.25 Billion |
|
ASICS CORP.(UNSP.ADR)/1
F:ASI
|
Germany | €313.13 Billion |
|
Bank of Beijing Co Ltd
SHG:601169
|
China | CN¥4.60 Trillion |
|
IONQ Inc
NYSE:IONQ
|
USA | $1.70 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down RENAU.UNSP.ARD 1/5 EO-20's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of RENAU.UNSP.ARD 1/5 EO-20 to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.87 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how RENAU.UNSP.ARD 1/5 EO-20's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for RENAU.UNSP.ARD 1/5 EO-20 (2022–2025)
The table below shows the annual total liabilities of RENAU.UNSP.ARD 1/5 EO-20 from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €3.86 Billion ≈ $4.51 Billion |
-8.85% |
| 2024-12-31 | €4.23 Billion ≈ $4.95 Billion |
-16.29% |
| 2023-12-31 | €5.06 Billion ≈ $5.91 Billion |
+98.19% |
| 2022-12-31 | €2.55 Billion ≈ $2.98 Billion |
-- |
About RENAU.UNSP.ARD 1/5 EO-20
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transp… Read more